Allogeneic HSCT is an option only for some younger MM patients, and clinicians should carefully evaluate the need for germline testing when considering a sibling donor. While MM remains incurable, the awareness of the MM patients’ risk for other POT1‐associated malignancies can advance the early detection of these cancers and their potential cure. This evidence concerns the gene POT1 and cancer.